10P3Me
10P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C101H151N23O29S2
- Masse moléculaire:2215.55
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
10P3Me (1 μCi per well; 0.5-4 h) exhibits significantly higher uptake in GPC3-high HepG2, Hep3B2.1-7, and Huh-7 cells compared to GPC3-low H1975 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
10P3Me (150-200 μCi; i.v.) exhibits high peak tumor uptake and an optimal tumor-to-liver ratio in HepG2 xenograft models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic nude mice (female, 4−6 weeks old, 18−22 g, subcutaneous xenograft hepatocellular carcinoma model)[1]
-
Dosage:200−300 μCi
-
Administration:i.v.; static scans at 60 and 120 min post-injection
-
Result:Reached peak tumor uptake of 5.62% ID/mL at 1 h and 3.53% ID/mL at 2 h post-injection in HepG2 xenograft models.
Achieved SUVmean of 5.09% ID/mL at 1 h, which was 3.97 times higher than in GPC3-low H1975 models.
Markedly reduced tumor accumulation in blocking groups and H1975 models.
-
Animal Model:Athymic nude mice (female, 4−6 weeks old, 18−22 g, orthotopic xenograft hepatocellular carcinoma model)[1]
-
Dosage:200−300 μCi
-
Administration:i.v.; PET imaging at 1 h post-injection
-
Result:Clearly localized intrahepatic tumor lesions in the left hepatic lobe via PET/CT imaging at 1 h post-injection, which was confirmed by surgical dissection.
-
Animal Model:Athymic nude mice (female, 4−6 weeks old, 18−22 g, subcutaneous xenograft hepatocellular carcinoma model)[1]
-
Dosage:150−200 μCi
-
Administration:i.v.; assessed at 10, 30, 60, 120, and 240 min post-injection
-
Result:Reached peak tumor uptake of 6.92% ID/g at 30 min post-injection.
Achieved a tumor-to-liver ratio of 8.28 at 60 min post-injection.
Chemical Information
-
Masse moléculaire 2215.55
-
Formule C101H151N23O29S2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
10P3Me Related Classifications
HY-P11618 Related Classifications
Powered by Bioz